Do Peptides Show Up on a Drug Test?
If you only want the short version. For a standard workplace test, no. The federal five-panel looks for marijuana, cocaine, amphetamines, opioids and PCP. A peptide is nothing like any of them.
In drug-tested sport the answer changes completely. Peptide hormones are prohibited at all times, dedicated tests exist, and the detection windows are shorter than the ban.
There is a third answer, and it is the one you rarely hear. A routine blood panel can show it. The marker anti-doping uses for growth hormone is IGF-1, and any doctor can order that test.
The question behind the question
A lot of people arriving here are not asking a factual question. They are asking whether they can get caught, and answering only the literal question would be a way of avoiding that one.
So here is the useful version of that. If a workplace panel is the thing worrying you, stop worrying. Those panels have never looked for a peptide and there is no sign that is changing.
What this page will not do is help anyone avoid a test that is looking, which is why there are no detection windows in hours for named compounds below. The figures circulating for those do not trace to published work, and printing them would only serve one purpose.
The two exposures worth your attention are different from the one most people check. One is medical, and it appears on a blood panel instead of a urine screen. The other applies only in tested sport, where the rules are strict and the tests are improving.
Why standard panels miss them
Only one of the two reasons is about chemistry.
A workplace urine screen begins with an immunoassay, which uses antibodies raised against specific small-molecule drug structures. Those antibodies bind what they were built to bind. A peptide is a chain of amino acids with no structural relationship to a cannabinoid or an opiate, so there is nothing on the panel for it to react with.
The second reason is money. Immunoassay is fast and cheap, which is why employers use it at scale. Identifying a specific peptide requires liquid chromatography with tandem mass spectrometry, which costs a great deal more per sample and needs a specialist laboratory.
Peptides are unlooked-for on those panels, for reasons that are economic and therefore changeable.
How anti-doping laboratories detect peptides
Anti-doping laboratories run three approaches, and the differences between them explain most of what follows.
The isoform test
This distinguishes pharmaceutical growth hormone, which is a single 22-kDa form, from the mixture of forms a pituitary produces. A shifted ratio implies an outside source. It is sensitive and its detection window is short.[^1]
The biomarker test
This measures two things growth hormone makes your body do: IGF-1, a short-term marker of liver response, and P-III-NP, a longer-term marker of collagen synthesis. Both rise in a dose-dependent way, and both can stay elevated for as long as a month after dosing stops.[^1]
Direct detection by mass spectrometry
This targets specific compounds and their urinary breakdown products. This is what catches the growth hormone releasing peptides, and it works on metabolites instead of the parent compound, since the parent clears within hours.[^2]
Those three cover different windows. The isoform test catches recent use precisely. The biomarker test catches older use imprecisely. Direct detection catches specific compounds if the sample is taken soon enough.
What the catch rate actually says
This figure gets quoted as a reassurance, and it does not support one.
Growth hormone doping tests came into use in 2004. Since then only a handful of athletes have been caught by them.[^3]
That reads as evidence that the tests do not work, and the researchers who run them read it differently. A reference review of hormone doping attributes the low detection rate to the limitations of the tests, meaning peptide hormones need blood instead of urine, the assays have low sensitivity, and the detection windows are brief. The review is explicit that this reflects the tests and not an absence of use.[^4]
The biomarker test was introduced at the London Olympics in 2012, where it caught two powerlifters that the isoform test had missed.[^3]
For an athlete the useful summary is narrower than the catch rate suggests. Testing is improving, samples are stored for retrospective analysis, and a negative result today is a statement about today's method.
Do peptides show up on a blood test?
More readers are affected by this than by the sport question.
IGF-1 is the marker anti-doping uses to detect growth hormone effects, and it is also an ordinary laboratory test. Endocrinologists order it. Anti-ageing clinics order it. People order it themselves through direct-to-consumer panels, often specifically to see whether a growth hormone peptide is working.
Anything that raises growth hormone raises IGF-1, which is the point of a secretagogue. Our guide to the growth hormone peptides covers how the two connect.
So a compound invisible to a workplace drug screen is plainly visible on a blood panel, if anyone looks at the right line. And the elevation persists: IGF-1 and P-III-NP can remain raised for up to a month after dosing ends.[^3]
That has three practical consequences worth spelling out.
A doctor investigating something unrelated may find a raised IGF-1 and pursue it. An unexplained result on that line is worth chasing, and the explanation only reaches them if you offer it.
Anyone using a secretagogue and also having routine bloods done should expect the question. Our injection site guide makes the same argument about telling a clinician what you took.
And if you order IGF-1 yourself to check whether something is working, a number that moves tells you the compound is doing its job. It tells you nothing about what happens downstream of that.
Does BPC-157 show up on a drug test? By testing context
The answer differs by who is testing you, and not in the way people expect.
Drug-tested sport
Peptide hormones, growth factors and their mimetics are prohibited at all times, in and out of competition, under section S2 of the prohibited list. That includes the growth hormone releasing peptides, the GHRH analogues, and the secretagogues. Our guide comparing peptides and steroids covers how the categories are drawn and where the catch-all sits.
Prescribed GLP-1 drugs
Semaglutide, tirzepatide and the rest are approved prescription medicines. No workplace panel screens for them, since the same immunoassay logic applies and there is no reagent for a peptide.
If a medical review officer asks, a prescription is the answer, and it is the same answer that covers any other prescribed medication. Anyone taking a compounded version through a telehealth service has a prescription too, and our guide on what peptide therapy costs sets out how those routes differ.
They also sit differently in sport from the growth hormone compounds, which surprises people who assume any injectable is banned. The current prohibited list is the place to check, and it is republished every January.
College sport
Collegiate banned drug classes include peptide hormones and growth factors as a class, which works differently from a list of named substances: a compound does not have to be named to be banned.
Standard employment
The federal five-panel and the wider ten-panel look for drugs of abuse, and no peptide appears on either.
Transport and federal safety roles
The Department of Transportation programme uses the same five-panel structure. No peptides.
Military
Routine urinalysis is built for drugs of abuse and run at volume, and it does not screen for peptide hormones. That is not permission, since a service member's obligations about what they take run through their chain of command and their medical provider, not through what a panel detects.
Insurance medicals are a different thing again
An insurance medical is not a drug test and it gets treated like one, which is a mistake with consequences a drug test does not carry.
A life or health insurance panel looks at liver and kidney markers, lipids, glucose and often more, and it is looking for evidence of your general health instead of drugs of abuse. Some of those markers can move for reasons connected to what you are taking, and an unexplained result invites questions.
The larger issue is the application form. Insurance applications ask what you take and what you have been treated for, and an inaccurate answer there is a contract problem, not a screening problem. That is a materially different risk from failing a urine test, and it is the one people rarely think about.
If you are applying for cover and taking something, that is a question for a broker or the insurer, not for a website.
What to declare, and to whom
The absence of a test is not the same as an absence of a question.
Any medical intake asking what you take is asking for a reason, and an unapproved compound omitted from that list is a gap in the information a clinician is working from. Our guide on when an injection site reaction means stop and get seen covers why this matters most at the point where something has gone wrong.
For athletes, a therapeutic use exemption is a real process that has to be applied for in advance. It covers a prescribed medicine, and a research-labelled vial bought online is outside it.
For anyone on prescribed peptide therapy, keep the prescription record. It answers the only question a medical review officer would have.
Where this stops being useful
Whether a specific test at a specific laboratory looks for a specific compound. Panels vary by employer contract and by collection site, and the only reliable answer comes from whoever is ordering the test.
Detection windows for individual compounds. Published figures come from small studies at particular doses, and the numbers circulating for research peptides are mostly not from anywhere.
What your employer would do with a positive result for something not on their panel, which is a question about employment law and not about chemistry.
Common questions
Does BPC-157 show up on a drug test?
Not on a standard workplace panel. Those screen for drugs of abuse using immunoassay, and there is no reagent on the panel that binds a peptide.
Do peptides show up on a DOT test?
No. The Department of Transportation programme uses the federal five-panel structure covering marijuana, cocaine, amphetamines, opioids and PCP.
Will a hair test find peptides?
Hair testing screens for the same categories of drug as urine testing. Peptide hormones are outside what it is built to find.
Can peptides be detected at all?
Yes, by laboratories that look. Anti-doping uses mass spectrometry for specific compounds and their metabolites, plus indirect tests measuring what growth hormone does to your body. Those are different tests from the ones an employer buys.
How long do peptides stay detectable?
For the growth hormone releasing peptides the parent compound clears within hours and laboratories target metabolites instead, which extends the window. The indirect biomarkers can stay elevated for as long as a month after dosing stops.
Do peptides show up on a normal blood test?
Not the compound itself, and its effects can. IGF-1 is a routine orderable test and anything raising growth hormone raises it. That is also the marker anti-doping uses.
Are peptides banned in the NCAA?
Peptide hormones and growth factors are banned as a class, which catches compounds nobody has listed by name.
Do GLP-1 drugs show up on a drug test?
No. Semaglutide and tirzepatide are prescription medicines and no workplace panel screens for them. If a medical review officer asks, a prescription answers it.
Will peptides affect a life insurance medical?
An insurance panel is not a drug test. It looks at liver, kidney, lipid and glucose markers, and an unexplained result can prompt questions. The bigger issue is the application form, where an inaccurate answer about what you take is a contract problem, not a screening one.
Should I tell my doctor?
Yes, and the reason is not the test. A clinician working from an incomplete list of what you take is working from bad information, and that matters most at the moment something goes wrong.
Sources
[^1]: WADA. Novel Biomarkers in Recombinant Human Growth Hormone Detection. Governing body research record, read at source. Describes the two established procedures: the hGH Isoforms Test, based on separate measurement of growth hormone isoforms by immunoassay, and the hGH Biomarkers Test, analysing the growth hormone responsive proteins IGF-1 and P-III-NP. States the drawbacks of each: a short window of opportunity for the isoforms test, and dependence on age and sex parameters plus more rapid elimination of IGF-1 than P-III-NP for the biomarkers test.
[^2]: Determination of growth hormone releasing peptides and their major metabolites in human urine for doping controls by liquid chromatography mass spectrometry. Analytical and Bioanalytical Chemistry, 2011. Establishes that anti-doping detection of GHRPs targets urinary metabolites rather than the parent compound, since the parent compound clears rapidly.
[^3]: The Use and Abuse of Growth Hormone in Sports. Endocrine Reviews 2019;40(4):1163. Peer-reviewed review, read via search result. Describes the isoform method and the marker method, and states that only a handful of athletes have been caught since growth hormone doping tests were implemented in 2004, attributing the low rate to the limitations of in-competition testing with current methods. Records that the biomarker test was introduced at the 2012 London Olympic and Paralympic Games, where it caught two power lifters missed by the isoform method. States that IGF-1 and P-III-NP both increase dose-dependently after growth hormone administration and can remain elevated for as long as a month after administration stops.
[^4]: Performance Enhancing Hormone Doping in Sport, Endotext, NCBI Bookshelf. Peer-reviewed reference chapter, read via search result. States that the low rate of detection of growth hormone doping may reflect the limitations of available tests for peptides and peptide hormones, which require blood rather than conventional urine sampling and feature low sensitivity and brief windows of detection, rather than a lack of abuse.
[^5]: SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs and Department of Transportation testing under 49 CFR Part 40. Regulatory. The federally mandated five-panel covers marijuana metabolites, cocaine metabolites, amphetamines, opioids and phencyclidine, with the ten-panel adding classes such as barbiturates, benzodiazepines and methadone depending on employer contract.